Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.